Search

everythinglearnresearchcommunity

for

Search:↓

The patient's long-term hair loss was caused by leukemia treatments and low estrogen levels, worsened by her genetic tendency for hair loss.

Activin increases skin tumor formation, skin Tregs help hair growth, lymph-node removal doesn't improve melanoma survival, cells can revert to stem cells in wound healing, and skin bacteria produce peptides that may treat infections.

Chemotherapy can cause various skin problems, and recognizing them helps improve patient care.

Skin aging and cancer development are influenced by the competition between stem cells.

Biomedical imaging has greatly improved understanding and treatment of solid tumors.

Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.

VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

Trichilemmal carcinoma shares genetic traits with other skin cancers, suggesting similar treatment options.

Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.

Vitamin A treatment reduced abnormal cell growth and improved skin conditions in rats with tumors.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

Chemotherapy and radiotherapy can cause skin side effects like rashes, hair loss, and nail changes, which are usually managed with conservative treatments.

Trichilemmal carcinoma shares genetic traits with other skin cancers, suggesting similar treatment options.

The link between anabolic agents and colorectal cancer risk is unclear.

Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.

Imatinib can cause hair loss due to lichen planopilaris.

A specific ATR gene mutation is linked to a hereditary oropharyngeal cancer syndrome.

TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.

Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.

T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Enhancing immune response can improve cancer treatment effectiveness.

Blocking mTORC1 reduces skin tumor growth in mice.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Hair protects the scalp from skin cancer by aiding immune defense.

EMT and metabolic pathways help cancer cells resist treatment and spread.

WNT10A helps esophageal cancer cells spread and keep renewing themselves.